Description

This edition of Genetic TOE profiles life sciences trends across diabetes and obesity management. The corresponding patent scenario is depicted along with the industry interactions.

The Genetic TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Diabetes, obesity, microbiome regulator, blood glucose modulation, epigenetic regulation, insulin glargine, lixisenatide combination, GLP1-glucagon receptor agonists